297 related articles for article (PubMed ID: 17189098)
1. The prophylactic effectiveness of various antifungal agents against the progression of trichosporonosis fungemia to disseminated disease in a neutropenic mouse model.
Tokimatsu I; Kushima H; Hashinaga K; Umeki K; Ohama M; Ishii H; Kishi K; Hiramatsu K; Kadota J
Int J Antimicrob Agents; 2007 Jan; 29(1):84-8. PubMed ID: 17189098
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice.
Kamberi P; Atsuro H; Takayoshi T; Masaru N
Chemotherapy; 1998; 44(1):55-62. PubMed ID: 9444410
[TBL] [Abstract][Full Text] [Related]
3. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Warn PA; Sharp A; Morrissey G; Denning DW
J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
5. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
Jandourek A; Brown P; Vazquez JA
Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
[No Abstract] [Full Text] [Related]
6. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
Bayramoglu G; Sonmez M; Tosun I; Aydin K; Aydin F
Infection; 2008 Feb; 36(1):68-70. PubMed ID: 17882360
[TBL] [Abstract][Full Text] [Related]
7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
8. Effect of antifungal treatment in a murine model of blastoschizomycosis.
Serena C; Mariné M; Marimon R; Pastor FJ; Guarro J
Int J Antimicrob Agents; 2007 Jan; 29(1):79-83. PubMed ID: 17134881
[TBL] [Abstract][Full Text] [Related]
9. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol.
Krcmery V; Mateicka F; Kunová A; Spánik S; Gyarfás J; Sycová Z; Trupl J
Support Care Cancer; 1999 Jan; 7(1):39-43. PubMed ID: 9926973
[TBL] [Abstract][Full Text] [Related]
10. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
11. Experimental disseminated trichosporonosis in mice: tissue distribution and therapy with antifungal agents.
Yamamoto K; Makimura K; Sudo T; Shibuya K; Uchida K; Yamaguchi H
J Med Vet Mycol; 1997; 35(6):411-8. PubMed ID: 9467108
[TBL] [Abstract][Full Text] [Related]
12. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole.
Khan ZU; Al-Sweih NA; Ahmad S; Al-Kazemi N; Khan S; Joseph L; Chandy R
J Clin Microbiol; 2007 Jun; 45(6):2025-7. PubMed ID: 17428940
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
14. Pathogenicity of Trichosporon asahii in a murine model of disseminated trichosporonosis.
Yang RY; Wang WL; Ao JH; Hao ZF; Zhang J; Wang CM
Chin Med J (Engl); 2008 Dec; 121(24):2557-60. PubMed ID: 19187595
[TBL] [Abstract][Full Text] [Related]
15. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Mariné M; Bom VL; de Castro PA; Winkelstroter LK; Ramalho LN; Brown NA; Goldman GH
Virulence; 2015; 6(5):476-86. PubMed ID: 25751127
[TBL] [Abstract][Full Text] [Related]
16. Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma.
Itoh K; Iwasaki H; Negoro E; Shigemi H; Tokimatsu I; Tsutani H; Yamauchi T
Mycopathologia; 2021 Mar; 186(1):113-117. PubMed ID: 33389484
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Trichosporon beigelii to antifungal agents.
Perparim K; Nagai H; Hashimoto A; Goto Y; Tashiro T; Nasu M
J Chemother; 1996 Dec; 8(6):445-8. PubMed ID: 8981185
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.
Bannatyne RM; Cheng PC; Fong IW
Infection; 1992; 20(3):168-70. PubMed ID: 1644494
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
Myoken Y; Kyo T; Kohara T; Fujihara M; Sugata T; Mikami Y
Clin Infect Dis; 2003 Jun; 36(11):1496-7. PubMed ID: 12766847
[No Abstract] [Full Text] [Related]
20. Disseminated Trichosporon asahii infection in a patient with acute myeloid leukemia.
Cardenas-de la Garza JA; Ancer-Arellano J; Cuellar-Barboza A; Saenz-Ibarra B; Ocampo-Garza SS; Barboza-Quintana O; Gallardo-Rocha A; Vera-Cabrera L; Ocampo-Candiani J; Welsh O
J Dermatol; 2019 Apr; 46(4):e128-e129. PubMed ID: 30295013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
